ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway.
ReNeuron will conduct head-to-head studies with its competitors to produce the data needed to achieve the commercial validation of the platform, Ross said. The company's cash runway has also been extended into 2024 following a restructuring undertaken in 2022, he added.